Y-mabs announces gpa33-sada data presented at aacr

New york, april 12, 2021 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that dr. sebastian chung from memorial sloan kettering cancer center (“msk”) presented a virtual poster discussing the sada technology platform for pre-targeted radioimmunotherapy against gpa33 in a xenograft model of colorectal peritoneal carcinomatosis at the american association for cancer research (“aacr”) annual meeting on april 10, 2021.
YMAB Ratings Summary
YMAB Quant Ranking